Erlotinib , ≥98% , 183321-74-6

CAS NO.：183321-74-6

Empirical Formula: C22H23N3O4

Molecular Weight: 393.44

MDL number: MFCD02089651

EINECS: 689-196-2

PRODUCT Properties

• Melting point: 159-160 °C
• Boiling point: 553.6±50.0 °C(Predicted)
• Density: 1.24
• storage temp.: Keep in dark place,Sealed in dry,Store in freezer, under -20°C
• solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• form: Solid
• pka: 5.32±0.30(Predicted)
• color: White
• InChI: InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
• InChIKey: AAKJLRGGTJKAMG-UHFFFAOYSA-N
• SMILES: N1=C2C(C=C(OCCOC)C(OCCOC)=C2)=C(NC2=CC=CC(C#C)=C2)N=C1
• CAS DataBase Reference: 183321-74-6(CAS DataBase Reference)

Description and Uses

Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC₅₀ = 2.5 μM). This inhibits tumor growth in human head and neck carcinoma HN5 tumor xenografts in mice with an ED₅₀ value of 9 mg/kg. Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC₅₀ = 4.6 μM) and JAK2 mutant JAK2^V617F positive hematopoietic progenitor cells (IC₅₀ = 5 μM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia. Formulations containing erlotinib have been used to treat certain forms of cancer, including non-small cell lung cancer.

Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM.

Safety

• Symbol(GHS): GHS08
• Signal word: Danger
• Hazard statements: H350-H304-H227
• Precautionary statements: P501-P202-P210-P201-P280-P370+P378-P331-P308+P313-P301+P310-P403+P235-P405
• Safety Statements: 24/25
• RTECS: VA0971100
• HS Code: 29335990
• Hazardous Substances Data: 183321-74-6(Hazardous Substances Data)